2007 Documentation Labelling 
RX Note
AUGUST 13, 2025
Introduction Once, I received a query from a ward nurse: If a product label mentioned that "Do not store over 25°C", is it fine for us to keep the medication in fridge? What does a cool place on the product label mean? Read the label to know the recommended storage temperature range.
Putting Patients First Blog
JUNE 26, 2025
This step would ensure that real-world considerations, such as off-label uses and quality-of-life impacts, are factored into revised pricing decisions. 4 Centers for Medicare & Medicaid Services, National Provider Communication Standards , April 15, 2025, https ://www.cms.gov/files/document/national-provider-communication-standards.pdf.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
OCTOBER 13, 2022
In July 2019, the MHRA held up Colonis for sending a letter to physicians advertising the off-label use of the drug in children and those with renal impairment. On 22 September, the MHRA expanded the label to include the use for sleep-onset insomnia in children with ADHD. Melatonin is used globally as a supplement to improve sleep.
European Pharmaceutical Review
DECEMBER 20, 2023
In October 2023, the European Parliament (EP) proposed revisions to the European Commission proposals with diverging views on various topics set out through two documents. In October 2023, the European Parliament (EP) proposed revisions to the European Commission proposals with diverging views on various topics set out through two documents.
RX Note
JUNE 4, 2023
Introduction Once, I received a query from a ward nurse: If a product label mentioned that "Do not store over 25°C", is it fine for us to keep the medication in fridge? What does a cool place on the product label mean? Read the label to know the recommended storage temperature range.
Pharma in Brief
JANUARY 17, 2021
The Court found that the prior art documents cited by Pharmascience ( Pinchasi 2007 and Karussis 2006 ) neither disclosed nor enabled the asserted claims of the 437 Patent. The Court rejected Pharmascience’s argument that the skilled person could have easily prescribed Copaxone ® 20 mg for the claimed use, though off-label.
FDA Law Blog: Biosimilars
MAY 11, 2023
GSK skinny label case , the U.S. Specifically, the Government explained, “[t]he section viii pathway cannot function properly if FDA and generic manufacturers cannot rely on an NDA holder’s representations to the agency regarding which portions of the brand-name drug’s labeling teach patented methods of use.”
Expert insights. Personalized for you.
Let's personalize your content